Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user is contemplating whether to continue or stop using these treatments.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

A 40-year-old shared progress pictures showing results after 3.5 months of using dutasteride for hair loss. The conversation likely discusses this specific treatment and its effects on hair regrowth.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

The conversation humorously discusses hair loss treatments, including finasteride, dutasteride, minoxidil, and microneedling. The user shares progress and thanks the pharmaceutical industry, with comments on the effectiveness and side effects of these treatments.

Setipiprant may help with hair maintenance but is not a guaranteed solution for everyone. Other treatments like minoxidil, finasteride, and topical spironolactone are discussed, with varying opinions on their effectiveness.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

A user stopped finasteride after 15 years due to severe side effects, which improved after quitting. They maintained most of their hair and are considering alternatives like topical treatments or RU58841.

A 48-year-old reported significant hair regrowth after two years using finasteride and minoxidil, with better results on the temples and using a dermastamp for the crown. The user experienced no side effects from the treatments.

A 30-year-old man experienced significant hair regrowth using only oral finasteride over 1 year and 10 months, with no side effects except increased libido. He started seeing results around the 3-4 month mark and takes finasteride every 2-3 days now, believing he may lose hair if he stops.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgen receptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.

A user's 14-month journey with finasteride, microneedling, and Nizoral to treat hair loss. They experienced some side effects such as ball ache, needing to pee constantly, and less semen, but the results were generally positive.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

Finasteride effectively maintained hairline stability for 11 years with no side effects. Consistency and early treatment were key to success.

User shares new hair growth stack including oral minox, daily rolling with minox application, niacin, and Dutasteride. Excited about progress and plans to update in two months.

The conversation is about a person's two-year hair regrowth progress using finasteride, minoxidil, ketoconazole, and microneedling. They are comparing their hair from April 21, 2022, to April 13, 2024.

The user is concerned about patchy hair regrowth after 5.5 months of treatment. They are questioning if more hair growth can be expected in the upcoming months.

Dutasteride capsules should not be bitten or opened due to their foul taste and potential caustic effects. Users shared experiences of accidentally biting capsules and the unpleasant taste, with some suggesting swallowing techniques to avoid this.

The conversation discusses the use of finasteride for hair loss, comparing every day (ED) versus every other day (EOD) dosing. It suggests that both dosing schedules can be effective, but individual tolerance may vary.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

The user has been using Minoxidil for 10 months, along with derma rolling and taking vitamin D. They plan to try g20026 or pyril once available.

A user who has seen improvements in their hair loss after taking finasteride and minoxidil once a day for 5 months. Other users offered advice and support, with some cautioning about potential side effects of the treatments.

The user reports positive progress in hair loss treatment using finasteride, minoxidil, Nizoral, and Nioxin products over four months. They hope for continued success and discuss potential side effects and shedding.

The user shared progress pictures showing hair improvement after using topical finasteride and minoxidil since October 2024. The photos were taken in June 2025.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The conversation is about a user taking a break from oral minoxidil due to persistent eye puffiness after two years of use. Suggestions include switching to topical minoxidil foam and adjusting the dosage to manage side effects.